Skip to content

Cost Profile and Budget Implications of Rechargeable Versus Non-rechargeable Sacral Neuromodulation Devices for Neurogenic Lower Urinary Tract Dysfunction

Cost Profile and Budget Implications of Rechargeable Versus Non-rechargeable Sacral Neuromodulation Devices for Neurogenic Lower Urinary Tract Dysfunction

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07173517
Acronym
SNM、NLUTD
Enrollment
268
Registered
2025-09-15
Start date
2025-10-01
Completion date
2026-04-30
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurogenic Lower Urinary Tract Dysfunction, Rechargeable Sacral Neuromodulation Device

Keywords

neurogenic lower urinary tract dysfunction, cost-savings, sacral neuromodulation, rechargeable

Brief summary

Traditional sacral neuromodulation devices are not rechargeable. In recent years, new rechargeable sacral neuromodulation devices have been developed and put into the market. The aim of this study was to evaluate the cost savings of a rechargeable sacral neuromodulation device versus a non-rechargeable sacral neuromodulation device for the treatment of neurogenic lower urinary tract dysfunction.

Detailed description

From August 2020 to January 2025, 41 rechargeable and 227 non-rechargeable SNM patients with neurogenic lower urinary tract dysfunction in ten centers were enrolled in this study. Demographic data, SNM treatment-related costs, and adverse events (e.g., treatment discontinuation, infection, surgical site pain, and lead dislocation or fracture) were recorded for each patient to estimate the costs of long-term SNM treatment with rechargeable versus nonrechargeable devices. SPSS 25.0 software was used for statistical analysis of the data. Measurement data were expressed as mean ± SD, count data were expressed as cases (%), and paired t test was used for comparison before and after treatment in the group. P \< 0.05 was considered statistically significant.

Interventions

None listed

Sponsors

Aerospace Center Hospital
CollaboratorOTHER
Shandong Provincial Hospital
CollaboratorOTHER_GOV
Second Affiliated Hospital of Xi'an Jiaotong University
CollaboratorOTHER
Beijing Hospital
CollaboratorOTHER_GOV
Xi'an Honghui Hospital
CollaboratorOTHER
The First Affiliated Hospital of Zhengzhou University
CollaboratorOTHER
Second Hospital of Jilin University
CollaboratorOTHER
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
CollaboratorOTHER
Tongji Hospital
CollaboratorOTHER
Qilu Hospital of Shandong University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* male and female patients with neurogenic lower urinary tract dysfunction who had failed conventional treatment * obstructive urinary retention and contraindications to SNM

Design outcomes

Primary

MeasureTime frameDescription
Costs associated with sacral neuromodulation therapyFrom August 2020 to January 2025Costs associated with sacral neuromodulation therapy

Countries

China

Contacts

Primary ContactYan Li, Ph.D degree
yanli@sdu.edu.cn+86 18560089113

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026